IP Library › Granted Patent US 12,539,302
Granted Patent B2
US 12,539,302 · App. 18/494,950 · Granted Feb 3, 2026

Methods and compositions for the treatment of hair loss

Inventor: John Edward Wurst (Poway, CA)
Assignee: Aneira Pharma, Inc.
A61K31/506A61K9/0014A61K31/222A61K31/25A61K31/5575A61K31/58A61K38/13A61K47/10A61K47/12A61K47/26A61P17/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,539,302
App. No.
18/494,950
Granted
Feb 3, 2026
Kind
B2
Abstract

Compositions and methods for the treatment of hair growth and the prevention of hair loss.

Claims (20)

1 . A pharmaceutical composition wherein the composition's active agents consist of 0.01% w/v-1.0% w/v latanoprost and 2-7% w/v minoxidil.

2 . The pharmaceutical composition of claim 1 which is useful for growing hair wherein the pharmaceutical composition further comprises one selected from the group consisting of polysorbate 60, oleyl alcohol and benzyl alcohol.

3 . The pharmaceutical composition of claim 1 which is useful for growing hair wherein the pharmaceutical composition further comprises one selected from the group consisting of polyethylene lauryl alcohol, diethethylene glycol monoethyl ether and polyethylene glycol.

4 . The pharmaceutical composition of claim 1 which is useful for growing hair wherein the pharmaceutical composition comprises 30%-60% w/v propylene glycol.

5 . The pharmaceutical composition of claim 4 wherein the pharmaceutical composition comprises 0.05%-0.10% w/v latanoprost and 3-6% w/v minoxidil wherein the composition grows hair when applied to the scalp.

6 . The pharmaceutical composition of claim 5 wherein 1 milliliter of the pharmaceutical composition is applied topically to the scalp once a day.

7 . The pharmaceutical composition of claim 5 wherein the pharmaceutical composition comprises 0.1%-1% w/v diethylene glycol monoethyl ether.

8 . The pharmaceutical composition of claim 7 wherein the pharmaceutical composition comprises 0.1%-3% w/v oleic acid.

9 . The pharmaceutical composition according to claim 1 that wherein the composition grows hair when applied to the scalp of humans.

10 . The pharmaceutical composition according to claim 4 that wherein the composition grows hair when applied to the scalp in humans who are suffering from alopecia areata.

11 . A pharmaceutical composition of claim 1 wherein the composition's active agents consist of 0.01%-0.10% w/v latanoprost and 2-7% w/v minoxidil and further comprising oleyl alcohol.

12 . The pharmaceutical composition of claim 11 wherein the composition further comprises 40-60% w/v propylene glycol, 20-30% w/v ethanol, 0.1%-1.0% w/v diethylene glycol monethyl ether, 0.1-1.0% oleyl alcohol and water.

13 . The pharmaceutical composition of claim 12 further comprising 50% w/v propylene glycol, 25-30% w/v ethanol, 0.1%-0.5% w/v diethylene glycol monethyl ether, 0.1-0.2% w/v oleyl alcohol and water.

14 . The pharmaceutical composition of claim 12 further comprising 40% w/v propylene glycol, 30% w/v ethanol, 0.1-0.5% w/v diethylene glycol monethyl ether, 0.1-0.2% w/v oleyl alcohol and water.

15 . The pharmaceutical composition of claim 11 wherein the composition further comprises 50% w/v propylene glycol, 30% w/v ethanol, 0.5% diethylene glycol monoethyl ether, 0.15% oleyl alcohol and water.

16 . The pharmaceutical composition of claim 11 further comprising 40% w/v propylene glycol, 30% w/v ethanol, 3.0% w/v diethylene glycol monethyl ether, 0.3% w/v oleyl alcohol and water.

17 . The pharmaceutical composition of claim 11 further comprising 50% w/v propylene glycol, 30% w/v ethanol, 0.1%-3.0% w/v diethylene glycol monethyl ether, oleyl alcohol and water.

18 . The pharmaceutical composition of claim 17 further comprising 50% w/v propylene glycol, 30% w/v ethanol, 0.5% w/v diethylene glycol monethyl ether, oleyl alcohol and water.

19 . The pharmaceutical composition of claim 17 further comprising 50% w/v propylene glycol, 30% w/v ethanol, diethylene glycol monethyl ether, 0.15% w/v oleyl alcohol and water.

20 . The pharmaceutical composition according to claim 5 wherein the active agents latanoprost and minoxidil act synergistically to grow hair to a greater extent than either active agent applied as a monotherapy at the same area of the scalp, at the same dose and at the same concentration, as the pharmaceutical composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2023
From: WURST, JOHN EDWARD
To: ANEIRA PHARMA, INC.
Reel/Frame 065354/0354 →
Continuity (7)
Continuation 17501130 · Oct 14, 2021
Continuation 17233507 · Apr 18, 2021
Continuation 16983740 · Aug 3, 2020
Provisional Application 63100611 · Mar 23, 2020
Provisional Application 62895869 · Sep 4, 2019
Provisional Application 62883809 · Aug 7, 2019
Related Publication 20240075034A1 · Mar 7, 2024
References Cited (126)
US 4139619A · Chidsey, III · 1979 [cited by applicant]
US 4596812A · Chidsey, III et al. · 1986 [cited by applicant]
US 4820512A · Grollier · 1989 [cited by applicant]
US 4828837A · Uster et al. · 1989 [cited by applicant]
US 5030442A · Uster et al. · 1991 [cited by applicant]
US 5225189A · Pena · 1993 [cited by applicant]
US 5407944A · Goldman · 1995 [cited by applicant]
US 5620980A · Samour · 1997 [cited by applicant]
US 5834014A · Weiner et al. · 1998 [cited by applicant]
US 6262105B1 · Johnstone · 2001 [cited by applicant]
US 6403649B1 · Woodward et al. · 2002 [cited by applicant]
US 6465514B1 · Hallam et al. · 2002 [cited by applicant]
US 6596266B2 · Catalfo et al. · 2003 [cited by applicant]
US 6946120B2 · So et al. · 2005 [cited by applicant]
US 7388029B2 · Delong et al. · 2008 [cited by applicant]
US 7442369B1 · Pena et al. · 2008 [cited by applicant]
US 7749489B2 · Malek · 2010 [cited by applicant]
US 7803357B2 · Cappello · 2010 [cited by applicant]
US 8038988B2 · Woodward et al. · 2011 [cited by applicant]
US 8293789B2 · Jimenez-Bayardo et al. · 2012 [cited by applicant]
US 8454945B2 · Mccook et al. · 2013 [cited by applicant]
US 8758733B2 · Ahluwalia et al. · 2014 [cited by applicant]
US 8906962B2 · Delong et al. · 2014 [cited by applicant]
US 9138480B2 · Trogden et al. · 2015 [cited by applicant]
US 9149484B2 · Warner et al. · 2015 [cited by applicant]
US 9226931B2 · Ahluwalia et al. · 2016 [cited by applicant]
US 9700503B2 · Woodward et al. · 2017 [cited by applicant]
US 9750750B2 · Trogden et al. · 2017 [cited by applicant]
US 9763359B2 · Chan · 2017 [cited by applicant]
US 9849140B2 · Warner et al. · 2017 [cited by applicant]
US 10188661B2 · Singer et al. · 2019 [cited by applicant]
US 10470992B2 · Sekhavat et al. · 2019 [cited by applicant]
US 20020077256A1 · Niemiec et al. · 2002 [cited by applicant]
US 20040082660A1 · Ueno · 2004 [cited by applicant]
US 20040115234A1 · Gewirtz · 2004 [cited by applicant]
US 20050079139A1 · Jacques et al. · 2005 [cited by applicant]
US 20070160562A1 · Brinkenhoff · 2007 [cited by applicant]
US 20080206156A1 · Cronk · 2008 [cited by applicant]
US 20100204335A1 · Beddingfield et al. · 2010 [cited by applicant]
US 20100210720A1 · Pilotaz et al. · 2010 [cited by applicant]
US 20110136912A1 · Ketelson · 2011 [cited by applicant]
US 20120129789A1 · Yoelin · 2012 [cited by applicant]
US 20130041025A1 · Walt et al. · 2013 [cited by applicant]
US 20130131095A1 · Dalko · 2013 [cited by applicant]
US 20140322148A1 · Jackson · 2014 [cited by applicant]
US 20150072963A1 · Cotsarelis et al. · 2015 [cited by applicant]
US 20160136071A1 · Corboy, Jr. · 2016 [cited by applicant]
US 20160213590A1 · Sekhavat et al. · 2016 [cited by applicant]
US 20160287704A1 · Herslöf · 2016 [cited by applicant]
US 20160346183A1 · Sekhavat · 2016 [cited by applicant]
US 20170181950A1 · Wu · 2017 [cited by applicant]
US 20180200263A1 · Grimes · 2018 [cited by applicant]
US 20210038601A1 · Wurst · 2021 [cited by applicant]
US 20210038683A1 · Wurst · 2021 [cited by applicant]
CA 2309373A1 · 2000 [cited by applicant]
EP 3494955A1 · 2019 [cited by applicant]
JP 2001002535A · 2001 [cited by applicant]
JP 2001511155A · 2001 [cited by applicant]
JP 2003155218A · 2003 [cited by applicant]
JP 2014510042A · 2014 [cited by applicant]
JP 20165112246 · 2016 [cited by applicant]
WO 1998033497A1 · 1998 [cited by applicant]
WO 2005013928A1 · 2005 [cited by applicant]
WO 2009151828A1 · 2009 [cited by applicant]
WO 2011081861A2 · 2011 [cited by applicant]
WO 2012106249A2 · 2012 [cited by applicant]
WO 2013078259A2 · 2013 [cited by applicant]
WO 2013106565A1 · 2013 [cited by applicant]
WO 2014158373 · 2014 [cited by applicant]
WO 2015176161A1 · 2015 [cited by applicant]
WO 2016124601A1 · 2016 [cited by applicant]
WO 2019034571A1 · 2019 [cited by applicant]
Baker SB, Dayan JH, Crane A, Kim S. The influence of brow shape on the perception of facial form and brow aesthetics. Plast Reconstr Surg. Jun. 2007;119(7):2240-2247. doi: 10.1097/01.prs.0000260771.76102.6c. PMID: 17519… [cited by applicant]
Sadr J, Jarudi I, Sinha P. The role of eyebrows in face recognition. Perception. 2003;32(3):285-93. doi: 10.1068/p5027. PMID: 12729380. [cited by applicant]
Van Der Velden EM, Drost BH, Ijsselmuiden OE, Baruchin AM, Hulsebosch HJ. Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol. Aug. 1998;37(8):617-21. doi: 10.1046/j.1365-4362.1998.00540… [cited by applicant]
Velez N, Khera P, English JC 3rd. Eyebrow loss: clinical review. Am J Clin Dermatol. 2007;8(6):337-46. doi: 10.2165/00128071-200708060-00003. PMID: 18039016. [cited by applicant]
Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast Surg. Feb. 2011;35(1):116-21. doi: 10.1007/s00266-010-9561-3. Epub Aug. 21, 2010. PMID: 20730536; PMCID: PMC3036812. [cited by applicant]
Vergilis-Kalner IJ. Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases. Dermatol Online J. Jun. 15, 2014;20(6):13030/qt1mc5v5mx. PMID: 24945645. [cited by applicant]
Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg. Jul. 2013;39(7):1079-87. doi: 10.1111/dsu.12199. Epub… [cited by applicant]
Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. Feb. 2008;153(3):410-9. doi: 10.1038/sj.bjp.0707434. Epub Aug. 27, 2007. PMID: 17721551; PMCID: PMC22417… [cited by applicant]
Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, an… [cited by applicant]
Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. Sep. 2010;36(9):1361-71. doi: 10.1111/j.1524-4725.2010.01522.x. PMID: 20384750. [cited by applicant]
Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. Apr. 26, 2010;4:349-58. doi: 10.2147/opth.s6480. PMID: 20463804; PMCID: PMC2861943. [cited by applicant]
Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost. Plast Surg Nurs. Apr.-Jun. 2015;35(2):82-91. doi: 10.1097/PSN.0000000000000097. PMID: 26020474. [cited by applicant]
Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol. Feb. 2014;41(2):149-52. doi: … [cited by applicant]
Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Derma… [cited by applicant]
Deprost et al., Treatment of severe alopecia areata by topical applications of cyclosporin A: comparative trial versus placebo in 43 patients; Kluwer Academic Publishers, Trends in Human Growth and Alopecia Research, 19… [cited by applicant]
Gihar et al., Topical cyclosporin in male pattrn alopecia, Journal of the American Academy of Dermotology, vol. 22, No. 2, Part 1, pp. 251-353, Feb. 1990. [cited by applicant]
Aditya Gupta, et al., Efficacy of Off-Label Treatments for the Management of Androgenetic Alopecia: A Review, Clinical Drug Investigation, Jan. 2019, 8 pages. [cited by applicant]
Ahmed Abdulhussein Kawen, Topical Minoxidil alone and with Lanoprost in Localized Alopecia Areata Treatment: Comparative Study (2019-2020), Systematic Review Pharmacy, vol. 11, Issue 4, pp. 164-169, 2020. [cited by applicant]
Amal Ahmad El-Ashmawy, et al, Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata, Journal of Dermatological Treatment, vol. 29, No. 1, Jun. 15, 2017, pp. 55-6… [cited by applicant]
Bloch et al., Latanoprost and minoxidil: Comparative double-blind , placebo-controlled study for the treatment of hair loss, Surg Cosmet Dermatol. Rio de Janeiro v.10 n.1 Jan.-Mar. 2018 p. 39-43, DOI: http://dx.doi.org/… [cited by applicant]
Clinical Investigation, A Prospective Study of Iridial Pigmentation and Eyelash Changes Due to Ophthalmic Treatment with Latanoprost, Japanese Journal of Ophthalmology, Mar. 2004, vol. 48, Issue 2, pp. 141-147 (first on… [cited by applicant]
Coleman, H., The Cosmetic Effects of Bimatoprost vs. Latanoprost vs. Travoprost vs. Placebo on Eyelash Growth. American Academy of Optometry, 2010, 3 pages. [cited by applicant]
Edited by Rowe et al., (2009), “Handbook of Pharmaceutical Excipients (6th ed.)”, London: APhA, (PhP) Pharmaceutical Press., pp. 468-470. (Year: 2009). [cited by applicant]
Feidler-Weiss, Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata, Journal of American Academy of Dermatology, vol. 16, No. 3, part 2, pp. 745-748, Mar. 1987. [cited by applicant]
Garg et al., Alpoecia areata: edivence-based treatments, Semin Cutan Med Sug., Mar. 2009, one page. [cited by applicant]
Gita Faghihi, et al., The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows, Eur J Dermatol, 2009; 19, pp. 586-587. [cited by applicant]
Hawkshaw et al., Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles, PLOS Biology Fifteenth Anniv… [cited by applicant]
Hideo Uno et al., Effect of Latanoprost on Hair Growth in the Bald Scalp of the Stump-tailed Macacque: A Pilot Study, Acta Derm Venereol, 2002, pp. 7-12. [cited by applicant]
Im Coronel-Perez, et al., Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis, DJEADV, 2010, No. 24, pp. 481-485. [cited by applicant]
Johnstone et al., Prostaglandin-Induced Hair Growth, Survey of Ophthalmology, vol. 47, supplement 1, Aug. 2002. [cited by applicant]
Jorge Ocampo-Garza, et al., New drugs under investigation for the treatment of alopecias, Expert Opinion on Investigational Drugs, Issn 1354-3784, Jan. 15, 2019, 34 pages. [cited by applicant]
Justine A. Ellis, et al., Male pattern baldness: current treatments, future prospects, Drug Discovery Today, vol. 13, No. 17/18, Sep. 2008, pp. 791-797. [cited by applicant]
Karzan G. Khidir, et al., The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias, The FASEB Journal, 27 (2), Feb. 2013, pp. 557-567. [cited by applicant]
Lauren L. Levy, et al., Female pattern alopecia: current perspectives, International Journal of Women's Health, Aug. 28, 2013, pp. 541-556. [cited by applicant]
Mccarey et al. “Low Incidence of Iris Pigmentation andEyelash Changes in 2 Randomized Clinical Trials with Unoprostone Isopropyl 0.15%” American Academy of Opthalmology, pp. 1480-1488, 2004. [cited by applicant]
Murad, et al, Treatment for facial alopecia areata: A systematic review with evidence-based analysis, Journal of American Dermatology, Apr. 14, 2017, 10 pages. [cited by applicant]
National Center for Biotechnology Information. “PubChem Compound Summary for CID 8146, Diethylene glycol monoethyl ether” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Diethylene-glycol-monoethyl-ether. Created Mar… [cited by applicant]
Osborne, David; Skin Penetration and Permeation Properties of Transcutol®—Neat or Diluted Mixtures, AAPS PharmSciTech, vol. 19, No. 8, Nov. 2018, pp. 3513-3533. [cited by applicant]
Ozyurt S., et al., Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost, Actas Dermosifiliogr, 2015, pp. 74-75. [cited by applicant]
Patel et al., Bioanalytical Method Development and Validation for Latanoprost Quantification in Pharmaceutical Opthalmic Microemulsion Formulation by RP-HPLC, Journal of Analytical & Bioanalytical Techniques, vol. 6, is… [cited by applicant]
Paula M. Oliveira, et al, LC-MS bioanalytical method for simultaneous determination of latanoprost and minoxidil in the skin, Journal of Pharmaceutical and Biomedical Analysis, Mar. 6, 2020, 26 pages. [cited by applicant]
Pfizer Manufacturing Belgium NV, Xalatan Package Insert for the 2.5 mL fill—Package of 1 Bottle, Aug. 2011, 14 pages. [cited by applicant]
Rajarshi Mukhopadhyay, et al, A rare complication from prostaglandin analogue therapy, Clinical and Experimental Optometry, 2009, 92:2, pp. 137-138. [cited by applicant]
S. Sasaki, et al, Influence of prostaglandin F2a and its analogues on hair regrowth and follicular melanogenesis in a murine model, Experimental Dermatology, 2005, pp. 323-328. [cited by applicant]
Sardesai et al, A Study to Evaluate the Efficacy of Various Topical Treatment Modalities for Alopecia Areata, International Journal of Trichology, Oct.-Dec. 2012, 4 (4), pp. 265-270. [cited by applicant]
Schweiger et al., Topical Bimatoprost for the Treatment of Eyebrow Hypotrichosis, Journal of Drugs in Dermatology, vol. II, Issue I, Jan. 2012, 106-108. [cited by applicant]
T. Ogiso, et al. Transfollicular Drug Delivery: Penetration of Drugs Through Human Scalp Skin and Comparison of Penetration Between Scalp and Abdominal Skins In Vitro, Journal of Drug Targeting, 2002, vol. 10 (5), pp. 3… [cited by applicant]
Ulrike Blume-Peytavi, et al., A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with… [cited by applicant]
Williams, et al., “Penetration Enhancers”, 2004, Advanced Drug Delivery Reviews, 56(5), pp. 603-618. (doc.org/10.1016/j.addr.2003.10.025) (Year: 2004). [cited by applicant]
Y. Liang et al, Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variat complexes, British Journal of Pharmacology, 2008, pp. 1079-1093. [cited by applicant]
Inoue, Adverse Reaction after Use of Latanoprost in Japanese Glaucoma Patients, Ophthalmological Society, 2006, 110 vol., No. 8, pp. 581-587. [cited by applicant]
Google English translation provided for INOUE, Adverse Reaction after Use of Latanoprost in Japanese Glaucoma Patients, Ophthalmological Society, 2006, 110 vol., No. 8, pp. 581-587. [cited by applicant]
Woodward, Bimatoprost: A Novel Antiglaucoma Agent, Cardiovascular Drug Reviews, vol. 22, No. 2, pp. 103-120, 2004. [cited by applicant]
Porter, Mouse models for human hair loss disorders, Journal Anatomical Society of Great Britain and Ireland 2003, 202, pp. 125-131, 2003. [cited by applicant]